• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Schulman IRB's Central Oncology Review Division adds Judith Carrithers

Schulman IRB's Central Oncology Review Division adds Judith Carrithers

October 4, 2016
CenterWatch Staff

Schulman IRB, a central IRB in customer service and technology, announced that Judith Carrithers, JD, MPA, will join its Central Oncology Review (COR) division October 15, 2016, as director of Oncology Services. Launching later in 2016, COR will provide collaborative, flexible IRB review services for oncology research centers seeking a more advanced level of partnership and service integration from a central IRB.

Carrithers previously served as assistant dean for Human Research Protection and director of the Human Research Protection Program at Johns Hopkins University School of Medicine. In her new role, Carrithers will work with Michele Russell-Einhorn, vice president of Oncology Services at Schulman IRB and former senior director of Dana-Farber Cancer Institute's Office for Human Research Studies, to build and lead COR.

"Carrithers and I are intimately familiar with the unique requirements of cancer research centers and institutional IRBs," said Russell-Einhorn. "COR combines our deep understanding of this environment with Schulman IRB's best-in-class customer service and compliance record, providing cancer research centers and their IRBs with unparalleled transparency and collaboration throughout the review process."

Recent regulatory activities, like NIH's single IRB policy and HHS' proposed changes to the "Common Rule," will require multicenter research studies to be overseen by a central IRB. The challenges of managing a centralized IRB review process have encouraged many research institutions to seek working relationships with external IRBs.

"We know that a one-size-fits-all approach won't work for institutions," said Michael Woods, president and CEO at Schulman IRB. "COR will customize services to meet each institution's needs, providing levels of reliable, sophisticated support far beyond what is currently available in the central IRB space."

At Johns Hopkins, Carrithers was responsible for the direct operations of seven IRBs, and she helped develop and manage the Johns Hopkins Clinical Research Network collaboration between Johns Hopkins and five regional hospitals. She also coordinated with the University's General Counsel, IRB chairs and administration to develop policies and procedures for the IRBs, affiliated hospitals, and more than 20 ancillary review committees. She led initiatives to create more efficient and effective IRB processes at Johns Hopkins and also collaborated with Sun Yat-sen University in Guangzhou, China, to assess and improve that university's clinical research capabilities.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing